The glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys.
about
Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a 'Case Study'Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents.Saxagliptin for the treatment of diabetes - a focus on safety.Pancreas Volume and Fat Deposition in Diabetes and Normal Physiology: Consideration of the Interplay Between Endocrine and Exocrine PancreasThe bone-preserving effects of exendin-4 in ovariectomized rats.
P2860
The glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
The glucagon-like peptide-1-ba ...... mice, rats, dogs and monkeys.
@en
The glucagon-like peptide-1-ba ...... mice, rats, dogs and monkeys.
@nl
type
label
The glucagon-like peptide-1-ba ...... mice, rats, dogs and monkeys.
@en
The glucagon-like peptide-1-ba ...... mice, rats, dogs and monkeys.
@nl
prefLabel
The glucagon-like peptide-1-ba ...... mice, rats, dogs and monkeys.
@en
The glucagon-like peptide-1-ba ...... mice, rats, dogs and monkeys.
@nl
P2093
P2860
P356
P1476
The glucagon-like peptide-1-ba ...... mice, rats, dogs and monkeys.
@en
P2093
A-M Bergholm
K D Chadwick
K Tatarkiewicz
M J Graziano
R S Mangipudy
T P Reilly
P2860
P304
P356
10.1111/DOM.12294
P577
2014-04-27T00:00:00Z